Cite
HARVARD Citation
Pautier, P. et al. (2020). A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study). European journal of cancer. pp. 31-37. [Online].